**Acknowledgement**

90 Lipoproteins – Role in Health and Diseases

**5. Summary** 

at-risk individuals for the development of premature ischemic cardiovascular diseases. Identification of the type of lipoprotein profile (atherogenic vs. non-atherogenic) by this innovative electrophoretic method for lipoprotein analysis in plasma represents a beneficial contribution to actual lipid diagnostics. This system provides the analysis of lipoprotein parameters but also offers new interpretation for lipoprotein profiles, including an actual

The Score of Anti-Atherogenic risk SAAR, newly introduced parameter, a ratio of nonatherogenic/atherogenic lipoproteins, also confirmes atherogenic lipoprotein constellation and determines the degree of the atherogenic risk of subjects with atherogenic

A new method of electrophoretic lipoprotein separation on polyacrylamide gel (PAG)using the Lipoprint LDL System can quantify non-atherogenic and atherogenic plasma lipoproteins, including small dense LDL, i.e. strong atherogenic lipoprotein subpopulations.

With respect to the predominance of a non-atherogenic or atherogenic lipoproteins in thewhole lipoprotein profile, this method distinguishes a non-atherogenic lipoprotein

The contribution of this method is to confirm the existence of a non-atherogenic type of hyper-betalipoproteinaemia and the existence of normolipidemia with atherogenic lipoprotein profile, along with the common and well-known atherogenic

According to our preliminary analysis of a normolipidemic population, an atherogenic

More than 40% of the examined individuals in the general group of subjects had an atherogenic lipoprotein profile phenotype B. These people represent an at-risk population.

However, the tools by which is possible to identify these individuals at risk for a

A non-atherogenic hyperbetalipoproteinemiaLDL1,2 can be identified, which represents approxmately 20% of examined individuals with hypercholesterolemia and 10% of individuals in a general group of subjects. HyperbetalipoproteinemiaLDL1,2 is not

associated with the premature development of arterial vascular impairment.

*Faculty of Medicine, Comenius University, Bratislava, Slovak Republic* 

lipoprotein profile was revealed in 6% of normolipidemic young healthy individuals.

profilephenotype A from an atherogenic lipoprotein profile phenotype B.

framework of the practising scheme for diagnostics and treatment of dyslipidemias.

normolipidemia ( Oravec 2007a; Oravec 2007b; Oravec 2010).

hyperlipoproteinemia and non-atherogenic normolipidemia.

cardiovascular event are limited.

*2nd Department of Internal Medicine,* 

**Author details** 

Stanislav Oravec

This study was supported by an EU structural research fund Interreg III AT-SR, project code: 1414-02-000-28 in years 2006-2008.

We would like to acknowledge the excellent technical assistance of MTA Barbara Reif, MTA Judith Trettler and MTA Karin Waitz, Krankenanstalten Dr.Dostal, Vienna, Austria and also to acknowledge the excellent technical assistance of MTA Olga Reinoldova, 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
